Grupo Clínico Asociado en Neurorología
Grupo Clínico Asociado
Cognitive impairment and dementias
Cerebrovascular diseases
Demyelinating diseases
Epilepsy
Extrapyramidal pathology
Pain / headaches

Coordinador
STAFF
Colaborador/a
Ana Isabel Pareja MartínezAntonio Salvador AliagaBegoña López PesqueraFrancisco Gascón GiménezJésica García UllJosé Andrés Domínguez MoránJosé María Salom JuanJosé Miguel Santonja LlabataDavid García López
Enfermero/a
Miriam Iborra Perales
Técnico/a
Apoyo
Publicaciones
Calcitonin gene-related peptide in migraine: from pathophysiology to treatment. Santos-Lasaosa S, Belvis R, Cuadrado M, Diaz-Insa S, Gago-Veiga A, Guerrero-Peral A, Huerta M, Irimia P, Lainez J, Latorre G, Leira R, Pascual J, Porta-Etessam J, Sanchez Del Rio M, Viguera J, Pozo-Rosich P. Neurologia. 2022 Jun;37(5):390-402. doi: 10.1016/j.nrleng.2019.03.025. PMID: 35672126
Case Report: exacerbation of relapses following mRNA COVID-19 vaccination in multiple sclerosis: a case series. Quintanilla-Bordas C, Gascon-Gimenez F, Alcala C, Paya M, Mallada J, Silla R, Carratala-Bosca S, Gasque-Rubio R, Castillo J, Casanova B. Frontiers in Neurology. 2022 Apr 27;13:897275. doi: 10.3389/fneur.2022.897275. PMID: 35572939
Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis. Vicente C, Lacruz L, Gascon F, Carratala S, Quintanilla-Bordas C, Sanz M, Carcelen-Gadea M, Mallada J, Carreres J, Torres L, Dominguez J, Canizares E, Gil-Perotin S, Cubas L, Rubio R, Castillo-Villalba J, Perez-Miralles F, Casanova B. Frontiers in Neurology. 2022 Oct 28;13:991596. doi: 10.3389/fneur.2022.991596. PMID: 36388220
Remission of graves disease after initiation of ocrelizumab in patients with multiple sclerosis. Casany-Fernandez R, Gascon-Gimenez F, Matarredona Solaz E, Pardo Lozano F, Dominguez-Moran J, Ferri Ciscar J, Real J. Thyroid. 2022 Nov 23. doi: 10.1089/thy.2022.0398. PMID: 36416241
Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis. Perez-Miralles F, Prefasi D, Garcia-Merino A, Ara J, Izquierdo G, Meca-Lallana V, Gascon-Gimenez F, Martinez-Gines M, Ramio-Torrenta L, Costa-Frossard L, Fernandez O, Moreno-Garcia S, Maurino J, Carreres-Polo J, Casanova B. Brain and Behavior. 2021 Apr;11(4):e02044. doi: 10.1002/brb3.2044. PMID: 33486890
Document of revision and updating of medication overuse headache (MOH). Gonzalez-Oria C, Belvis R, Cuadrado M, Diaz-Insa S, Guerrero-Peral A, Huerta M, Irimia P, Lainez Andrés J, Latorre G, Leira R, Oterino A, Pascual J, Porta-Etessam J, Pozo-Rosich P, Sanchez Del Rio M, Santos-Lasaosa S. Neurologia. 2021 Apr;36(3):229-240. doi: 10.1016/j.nrl.2020.04.029. PMID: 32917437
Neuromodulation in headache and craniofacial neuralgia: guidelines from the Spanish Society of Neurology and the Spanish Society of Neurosurgery. Belvis R, Irimia P, Seijo-Fernandez F, Paz J, Garcia March G, Santos-Lasaosa S, Latorre G, Gonzalez-Oria C, Rodriguez R, Pozo-Rosich P, Lainez Andrés J. Neurologia. 2021;36(1):61-79. doi: 10.1016/j.nrl.2020.04.022. PMID: 32718873
Present and Future of Parkinson’s Disease in Spain: PARKINSON-2030 Delphi Project. Santos Garcia D, Blazquez-Estrada M, Calopa M, Escamilla-Sevilla F, Freire E, Garcia Ruiz P, Grandas F, Kulisevsky J, Lopez-Manzanares L, Martinez Castrillo J, Mir P, Pagonabarraga J, Perez-Errazquin F, Salom J, Tijero B, Valldeoriola F, Yanez R, Aviles A, Luquin M. Brain Sciences. 2021 Jul 31;11(8):1027. doi: 10.3390/brainsci11081027. PMID: 34439646
Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs. Santamarina E, Bertol V, Garayoa V, Garcia-Gomara M, Garamendi-Ruiz I, Giner P, Aranzabal I, Piera Balbastre A, Arcos C, Esteve P, Marinas A, Garcia-Escriva A, Viloria-Alebesque A, Loro F, Ponz De Tienda A, Olivan J, Bonet M, Davila-Gonzalez P, Sivera R, Molins A, Sansa G, Roche J, Martinez A, Monteagudo S, Casadevall T. Seizure. 2020 Dec;83:48-56. doi: 10.1016/j.seizure.2020.09.026. PMID: 33096456
Evaluation of the concomitant use of oral preventive treatments and Onabotulinumtoxin A in chronic migraine: the PREVENBOX study. Alpuente A, Gallardo V, Torres-Ferrus M, Santos-Lasaosa S, Guerrero A, Lainez Andrés J, Viguera J, Gago-Veiga A, Irimia P, Del Rio M, Pozo-Rosich P. European Journal of Neurology. 2020 Oct;27(10):2102-2108. doi: 10.1111/ene.14331. PMID: 32421912
Evidence of and experience with the use of onabotulinumtoxinA in trigeminal neuralgia and primary headaches other than chronic migraine. Santos-Lasaosa S, Cuadrado M, Gago-Veiga A, Guerrero-Peral A, Irimia P, Lainez Andrés J, Leira R, Pascual J, Porta-Etessam J, Sánchez Del Río M, Viguera Romero J, Pozo-Rosich P. Neurologia. 2020 Oct;35(8):568-578. doi: 10.1016/j.nrl.2017.09.003. PMID: 29169811
Will neurological care change over the next 5 years due to the COVID-19 pandemic?. Matias-Guiu J, Matias-Guiu J, Alvarez-Sabin J, Ramon Ara J, Arenillas J, Casado-Naranjo I, Castellanos M, Jimenez-Hernandez M, Lainez Andrés J, Moral E, Morales A, Rodriguez-Antiguedad A, Segura T, Serrano-Castro P, Diez-Tejedor E. Neurologia. 2020 May;35(4):252-257. doi: 10.1016/j.nrl.2020.04.006. PMID: 32364126
+ Información
Doctorando: Suller Marti, Ana
Director: Láinez Andres, Jose Miguel
Fecha: 21/03/2022
Universidad: Universitat de València
Título: Tratamiento endovascular en el ictus isquémico agudo. Análisis de factores pronóstico y de identificación etiológica
Doctorando: Piera Balbastre, Ana
Director: Láinez Andres, Jose Miguel; Ponz De Tienda, Alejandro
Fecha: 15/12/2020
Universidad: Universitat de València